These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8697057)

  • 1. Clinical studies with mazindol.
    Inoue S
    Obes Res; 1995 Nov; 3 Suppl 4():549S-552S. PubMed ID: 8697057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mazindol on body weight and insulin sensitivity in severely obese patients after a very-low-calorie diet therapy.
    Nishikawa T; Iizuka T; Omura M; Kuramoto N; Miki T; Ito H; Chiba S
    Endocr J; 1996 Dec; 43(6):671-7. PubMed ID: 9075607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.
    Inoue S; Egawa M; Satoh S; Saito M; Suzuki H; Kumahara Y; Abe M; Kumagai A; Goto Y; Shizume K
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):199S-202S. PubMed ID: 1728834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mazindol in two patients with Prader-Willi syndrome.
    Itoh M; Koeda T; Ohno K; Takeshita K
    Pediatr Neurol; 1995 Nov; 13(4):349-51. PubMed ID: 8771175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Appetite depressants: do they carry any weight?].
    Cluysenaer OJ; Tjoeng MM
    Ned Tijdschr Geneeskd; 1987 Mar; 131(10):388-91. PubMed ID: 3561533
    [No Abstract]   [Full Text] [Related]  

  • 6. A case of Prader-Willi syndrome with long-term mazindol treatment.
    Inui A; Uemoto M; Takamiya S; Shibuya Y; Baba S; Kasuga M
    Arch Intern Med; 1997 Feb; 157(4):464. PubMed ID: 9046903
    [No Abstract]   [Full Text] [Related]  

  • 7. [Long-term treatment of patients with obesity using mazindol and a reducing diet].
    van Seters AP; Bouwhuis-Hoogerwerf ML; Goslings BM; van Nieuwkoop L; van Slooten H; Struijk-Wielinga T
    Ned Tijdschr Geneeskd; 1982 May; 126(22):990-4. PubMed ID: 7110390
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mazindol].
    Mori Y
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():683-6. PubMed ID: 21766681
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of diet, exercise and anorexigenic drugs on serum thyroid hormones.
    Sonka J; Límanová Z; Zbirková A; Kratochvíl O
    Endokrinologie; 1980 Dec; 76(3):351-6. PubMed ID: 7472292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical cost savings of treating obesity with weight loss medications.
    Greenway FL; Ryan DH; Bray GA; Rood JC; Tucker EW; Smith SR
    Obes Res; 1999 Nov; 7(6):523-31. PubMed ID: 10574509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of obesity using appetite depressants].
    Ikeda Y
    Nihon Naika Gakkai Zasshi; 1995 Aug; 84(8):1290-4. PubMed ID: 7594950
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of an anorectic agent, AN 448 on weight reduction and plasma lipids.
    Ishikawa T; Nakaya N; Nakamura H; Goto Y
    Keio J Med; 1975 Jul; 24(3):211-8. PubMed ID: 1219154
    [No Abstract]   [Full Text] [Related]  

  • 13. Mazindol (Teronac)- another anorectic drug.
    Drug Ther Bull; 1974 Dec; 12(26):101-2. PubMed ID: 4459058
    [No Abstract]   [Full Text] [Related]  

  • 14. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG
    Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mazindol, an anorectic of a new series, in the treatment of obesity (author's transl)].
    Dolecek R
    Cas Lek Cesk; 1975 Feb; 114(8):249-54. PubMed ID: 1095197
    [No Abstract]   [Full Text] [Related]  

  • 17. Three controlled trials of weight loss with phenylpropanolamine.
    Altschuler S; Conte A; Sebok M; Marlin RL; Winick C
    Int J Obes; 1982; 6(6):549-56. PubMed ID: 6761288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anorexiant drugs in the ambulant treatment of obese patients (author's transl)].
    Jenny S; Zimmermann KG; Radielovic P; Bühlmann AA
    Schweiz Rundsch Med Prax; 1976 Jul; 65(28):874-8. PubMed ID: 1005298
    [No Abstract]   [Full Text] [Related]  

  • 19. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity.
    Enzi G; Baritussio A; Marchiori E; Crepaldi G
    J Int Med Res; 1976; 4(5):305-18. PubMed ID: 1028632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
    Lucchetta RC; Riveros BS; Pontarolo R; Radominski RB; Otuki MF; Fernandez-Llimos F; Correr CJ
    Clinics (Sao Paulo); 2017 May; 72(5):317-324. PubMed ID: 28591345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.